Global Allergy & Airways Patient Platform (GAAPP) is a leading brand dedicated to improving the lives of individuals with airways, allergic, and atopic conditions. They have collaborated with experts and researchers worldwide to co-author over 20 publications and incorporate the most relevant international guidelines. GAAPP's publications cover a wide range of topics, including asthma, allergies, atopic dermatitis, COPD, eosinophil-driven diseases, and urticaria.

These resources provide invaluable insights and information for healthcare professionals, patients, and caregivers. One notable publication by GAAPP focuses on improving care in eosinophil-associated diseases (EADs) by outlining key patient rights, expectations, and an ambitious action plan to enhance health outcomes for individuals with EADs. Another important publication emphasizes the need to fundamentally change the role of oral corticosteroids in the management of asthma.

By offering a wealth of knowledge through their publications and international guidelines, GAAPP aims to empower healthcare professionals, support patients in making informed decisions, and ultimately improve the quality of care and health outcomes for individuals with airways, allergic, and atopic conditions